Literature DB >> 17391276

P2Y2- and P2Y4 purinergic receptors are over-expressed in human colon cancer.

G Nylund1, L Hultman, S Nordgren, D S Delbro.   

Abstract

1. A characteristic of cancer is altered signal transduction leading to uninhibited growth. Adenosine-5'-triphosphate (ATP), a natural ligand at P2X- and P2Y purinergic receptors may regulate cell growth in non-neoplastic, as well as neoplastic tissues. In the human colon cancer cell line, HT-29, we previously demonstrated the expression of purinergic receptors of the P2Y(2)- and P2Y(4) subclasses. 2. The aim of the current study was to investigate whether these two purinergic receptors are expressed also in human colon cancer, and, if so, how such expression is related to that in tumour-free colonic tissue. 3. The immunohistochemical findings of both P2Y(2)- and P2Y(4) receptors in the tumours from three patients, prompted us to conduct an investigation of a consecutive series of patients utilizing Western blotting for protein detection and densitometry for quantitation. 4. Both P2Y(2)- and P2Y(4) purinergic receptors could be identified in tumour-free tissue, and both were significantly over-expressed in each of the 10 colon cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391276     DOI: 10.1111/j.1474-8673.2007.00389.x

Source DB:  PubMed          Journal:  Auton Autacoid Pharmacol        ISSN: 1474-8665


  24 in total

1.  The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP.

Authors:  Rui Xie; Jingyu Xu; Guorong Wen; Hai Jin; Xuemei Liu; Yuan Yang; Bei Ji; Yixia Jiang; Penghong Song; Hui Dong; Biguang Tuo
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

2.  Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer.

Authors:  Beat M Künzli; Maria-Isabell Bernlochner; Stephan Rath; Samuel Käser; Eva Csizmadia; Keiichi Enjyoji; Peter Cowan; Anthony d'Apice; Karen Dwyer; Robert Rosenberg; Aurel Perren; Helmut Friess; Christoph A Maurer; Simon C Robson
Journal:  Purinergic Signal       Date:  2011-04-02       Impact factor: 3.765

3.  Reviewing the role of P2Y receptors in specific gastrointestinal cancers.

Authors:  Steve Dagenais Bellefeuille; Caroline M Molle; Fernand-Pierre Gendron
Journal:  Purinergic Signal       Date:  2019-09-02       Impact factor: 3.765

4.  P2Y2 receptor expression is altered in rats after spinal cord injury.

Authors:  Ana E Rodríguez-Zayas; Aranza I Torrado; Jorge D Miranda
Journal:  Int J Dev Neurosci       Date:  2010-07-07       Impact factor: 2.457

Review 5.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 6.  Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Authors:  Tamás Deli; László Csernoch
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

7.  P2Y2 receptor transcription is increased by NF-kappa B and stimulates cyclooxygenase-2 expression and PGE2 released by intestinal epithelial cells.

Authors:  Emilie Degagné; Djordje M Grbic; Andrée-Anne Dupuis; Elise G Lavoie; Christine Langlois; Nishant Jain; Gary A Weisman; Jean Sévigny; Fernand-Pierre Gendron
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

Review 8.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

Review 9.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

10.  P2Y2 receptors mediate nucleotide-induced EGFR phosphorylation and stimulate proliferation and tumorigenesis of head and neck squamous cell carcinoma cell lines.

Authors:  Lucas T Woods; Kimberly J Jasmer; Kevin Muñoz Forti; Vinit C Shanbhag; Jean M Camden; Laurie Erb; Michael J Petris; Gary A Weisman
Journal:  Oral Oncol       Date:  2020-06-12       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.